首页|甘海胃康胶囊联合阿莫西林和艾司奥美拉唑二联疗法治疗消化性溃疡的临床研究

甘海胃康胶囊联合阿莫西林和艾司奥美拉唑二联疗法治疗消化性溃疡的临床研究

扫码查看
目的 探讨甘海胃康胶囊联合阿莫西林胶囊和艾司奥美拉唑镁肠溶片二联疗法治疗消化性溃疡的临床疗效。方法 选取2021年12月-2023年6月青岛市第八人民医院收治的204例消化性溃疡患者,按随机数字表法分为对照组和治疗组,每组各102例。对照组患者口服阿莫西林胶囊,3粒/次,4次/d,持续治疗14 d,然后停药;口服艾司奥美拉唑镁肠溶片,1片/次,4次/d,持续治疗14 d,然后维持剂量1片/次,1次/d,持续治疗2周。治疗组在对照组基础上口服甘海胃康胶囊,6粒/次,3次/d,持续治疗4周。比较两组的临床疗效、胃镜疗效、幽门螺杆菌转阴率、症状缓解时间和血清指标。结果 治疗后,治疗组的临床疗效总有效率为94。12%,对照组的临床疗效总有效率为85。29%,组间比较差异显著(P<0。05)。治疗后,治疗组的胃镜疗效总有效率为96。08%,对照组的胃镜疗效总有效率为87。25%,组间比较差异显著(P<0。05)。治疗组患者幽门螺杆菌转阴率96。08%高于对照组的88。24%,组间差异有统计学意义(P<0。05)。治疗组的腹痛、烧心、反酸缓解时间明显短于对照组,差异有统计学意义(P<0。05)。治疗后,两组的血清白细胞介素-17(IL-17)、肿瘤坏死因子-α(TNF-α)、内皮素(ET)水平均显著降低(P<0。05),且治疗组血清IL-17、TNF-α、ET水平低于对照组(P<0。05)。结论 甘海胃康胶囊联合阿莫西林胶囊和艾司奥美拉唑镁肠溶片二联疗法可提高消化性溃疡的疗效,提高幽门螺杆菌转阴率,促进症状缓解,减轻炎症反应。
Clinical study on Ganhai Weikang Capsules combined with amoxicillin and esomeprazole dual therapy regimen in treatment of peptic ulcers
Objective To investigate the curative effect of Ganhai Weikang Capsules combined with Amoxicillin Capsules and Esomeprazole Magnesium Enteric-coated Tablets in treatment of peptic ulcers. Methods 204 Patients with peptic ulcers admitted to Qingdao Eighth People's Hospital from December 2021 to June 2023 were divided into control group and a treatment group using a random number table method,with 102 patients in each group. Patients in the control group were treated with Amoxicillin Capsules,3 grains/time,4 times daily,for 14 d,and then stopped. Esomeprazole Magnesium Enteric-coated Tablets were taken orally,1 tablet/time,4 times daily,for 14 d,and then the maintenance dose was 1 tablet/time,once daily,for 2 weeks. Patients in the treatment group were given Ganhai Weikang Capsules,6 grains/time,3 times/day,for 4 weeks on the basis of control group. The clinical efficacy,gastroscopic efficacy,Helicobacter pylori negative conversion rate,duration of symptom remission,and serum factors of the two groups were compared. Results After treatment,the total effective rate of clinical efficacy in the treatment group (94.12%) was higher than that in the control group (85.29%),and the difference between groups was significant (P<0.05). After treatment,the total effective rate of gastroscopy efficacy in the treatment group (96.08%) was higher than that of the control group (87.25%),and the difference between groups was significant (P<0.05). After treatment,H. pylori negative conversion rate in the treatment group (96.08%) was higher than that in the control group (88.24%),and the difference between groups was significant (P<0.05). After treatment,the remission time of abdominal pain,heartburn,and acid reflux in treatment group was shorer than that in control group (P<0.05). After treatment,the serum levels of IL-17,TNF-α,and ET were significantly decreased in two groups (P<0.05),and the serum levels of IL-17,TNF-α,and ET in treatment group was greater than those in the control group (P<0.05). Conclusion Ganhai Weikang Capsules combined with Amoxicillin Capsules and Esomeprazole Magnesium Enteric-coated Tablets can improve the curative effect of peptic ulcers,increase the H. pylori negative conversion rate,promote the remission of symptoms,and reduce inflammation.

Ganhai Weikang CapsulesAmoxicillin CapsulesEsomeprazole Magnesium Enteric-coated Tabletspeptic ulcerHelicobacter pylori negative conversion rateacid reflux remission timeIL-17TNF-α

袁泽宇、宋玉君、王芳、郭英杰、贺庆娟

展开 >

青岛市第八人民医院消化内科,山东 青岛 266000

青岛市第八人民医院中医科,山东 青岛 266000

青岛大学附属医院消化内科,山东 青岛 266000

甘海胃康胶囊 阿莫西林胶囊 艾司奥美拉唑镁肠溶片 消化性溃疡 幽门螺杆菌转阴率 反酸缓解时间 白细胞介素-17 肿瘤坏死因子-α

山东省中医药科技项目青岛市医药科研指导计划项目

M-2023190T2020-WJZD112

2024

现代药物与临床
天津药物研究院,中国药学会

现代药物与临床

CSTPCD
影响因子:1.179
ISSN:1674-5515
年,卷(期):2024.39(9)
  • 14